The clinical immuno-monitoring platform (CyTOF mass cytometry, flow cytometry and Fluidigm) allows the comprehensive and in-depth analysis of patient samples. These technologies have different advantages that combine to provide the profiling necessary to support the development of new diagnostic tests and clinical trials, as well as transplant center activities and basic, clinical and translational research.
The Center for Immunotherapy and Vaccinology (VIC) was created in 2001 by Professor Giuseppe Pantaleo, Head of the Immunology and Allergy Department of the University Hospital of Lausanne (CHUV).
Between 2007 and 2021, the VIC was part of the HVTN (HIV Vaccine trial Network). Their mission is to fully characterize the safety, immunogenicity and efficacy of HIV vaccine candidates with the goal of developing a safe and effective vaccine as quickly as possible for HIV prevention worldwide.
The main goals of the clinical immuno-monitoring platform are to identify immunological profiles (or profiling) associated with different infectious agents, cancers, autoimmune or hematological diseases. Profiling consists in characterizing cells and tissues at the phenotypic, functional and genetic levels. This characterization allows the association between the immunological profile of a patient and the development of his disease.